tbuckley/cabot-search huggingface dataset:
Ventricular Assist Device in Acute Myocardial Infarction
Authors: Deepak Acharya, Renzo Y. Loyaga-Rendon, Salpy V. Pamboukian, José A. Tallaj, William L. Holman, Ryan S. Cantor, David C. Naftel, James K. Kirklin
Journal: Journal of the American College of Cardiology (2016)
Familial Hyperproinsulinemia Due to a Proposed Defect in Conversion of Proinsulin to Insulin
Authors: Philip A. Gruppuso, Phillip Gorden, C. Ronald Kahn, Marvin Cornblath, W. Patrick Zeller, Robert Schwartz
Journal: New England Journal of Medicine (1984)

Familial hyperproinsulinemia is a genetic disorder characterized by elevated plasma levels of proinsulin-like material. In two previously described kindreds this has been shown to be due to a structural abnormality in the proinsulin molecule. We have identified a third family with hyperproinsulinemia in which there appeared to be a different defect. The propositus, a 12-year-old girl, had borderline glucose intolerance and markedly elevated immunoreactive-insulin levels on oral glucose-tolerance testing. Gel filtration of plasma revealed that 66 per cent of circulating insulin immunoreactivity was accounted for by the proinsulin-like components. Two of four siblings, the father, and the paternal grandfather also had elevated fasting insulin immunoreactivity in the presence of normal plasma glucose concentrations and elevated levels of proinsulin-like material. In vitro tryptic digestion of plasma proinsulin-like material from an affected family member revealed that proinsulin was converted to insulin in a manner indistinguishable from that in the control. Similarly, proinsulin and insulin exhibited normal activity in a radioreceptor assay. These findings suggest that the proinsulin molecule in this family was normal and that hyperproinsulinemia was due to a defect in the conversion of proinsulin to insulin.
Prophylactic Sclerotherapy of Large Esophageal Varices
Authors: William C. Santangelo, Maria I. Dueno, Boyce L. Estes, Guenter J. Krejs
Journal: New England Journal of Medicine (1988)

We randomly assigned 95 patients with large esophageal varices (Grade 3 or 4) who had not previously had upper gastrointestinal tract bleeding to two groups: 49 received intravariceal sclerotherapy, and 46 were followed as controls. Over a mean follow-up of 13 months there was no difference between the sclerotherapy group and the control group in mortality (24.4 percent) or any significant difference in average hospital stay per month (3.0 vs. 2.6 days). Sclerotherapy was associated with significantly more episodes of upper gastrointestinal bleeding (26 vs. 10 episodes, P<0.05); 75 percent of deaths in the sclerotherapy group were related to bleeding, as compared with 18 percent in the control group. An additional 54 patients with cirrhosis who did not qualify for the study were also followed — 20 with small varices and 34 with none. Mortality was 20 and 15 percent, respectively; no deaths were due to bleeding. We conclude that prophylactic sclerotherapy does not provide clinical benefit to patients with large esophageal varices. (N Engl J Med 1988; 318:814–8.)
Case 31-2010
Authors: Arnold N. Weinberg, John A. Branda
Journal: New England Journal of Medicine (2010)

A 29-year-old woman was admitted to the hospital because of swelling, erythema, and pain of the hand at the site of a cat bite. Despite treatment with amoxicillin–clavulanic acid, her symptoms worsened and fever, chills, headache, and arthralgias developed.
Abstract P4-09-01: FGFR1 protein expression is associated with prognosis in primary breast cancer: A comprehensive analysis of gene copy number, mRNA and protein expression
Authors: M Tomiguchi, Y Yamamoto, M Yamamoto-Ibusuki, R Yamaguchi, Y Fujiki, S Fujiwara, A Sueta, T Takeshita, T Inao, H Iwase
Journal: Cancer Research (2016)

Abstract Background: The Cancer Genome Atlas (TCGA) showed that copy number gain/amplification of FGFR1 was around 10% in primary breast cancer. FGFR1 gene amplification in breast cancer has been reported in some studies, more likely seen in ER-positive subtype. Several preclinical and clinical studies demonstrated that FGFR1 was one of novel targets of therapy for metastatic breast cancer. Previous studies suggested that aberrant FGFR1 expression was associated with poor prognosis, while there was no report that compared copy number aberration, mRNA and protein expression. The aim of this study is to analyze FGFR1 gene copy number, expression levels of FGFR1 mRNA and FGFR1 protein in ER-positive/HER2-negative primary breast cancer, and to examine the relationship between FGFR1 status and clinicopathological parameters including prognosis. Methods: The cohort of this study included 307 ER-positive/HER2-negative primary invasive breast cancer patients treated with standard care at Kumamoto University Hospital between June 2000 and January 2011. We performed a comprehensive analysis of FGFR1 at the levels of gene copy number, mRNA and FGFR1 protein expression analyzed by qPCR, qRT-PCR and immunohistochemistry, respectively. Results: FGFR1 gain/amplification was identified in 43 (14.0%) out of 307 patients. FGFR1 gain/amplification had significantly associated with higher nuclear grade (p=0.010). No correlations between FGFR1 mRNA expression levels and any clinicopathological factors were found. Expression levels of FGFR1 protein was positively associated with invasive tumor size (p=0.039). Modest positive correlations between these three (FGFR1 gene gain/amplification, expression levels of FGFR1 mRNA and FGFR1 protein) were found. The univariate analysis revealed that high FGFR1 protein expression was significantly related to poor prognosis (p=0.0019, HR: 2.63, 95%CI: 1.17-5.98) in terms of relapse-free survival (RFS) but not breast cancer-specific survival. The univariate analysis did not show that any factors except FGFR1 protein expression were significantly associated with RFS in this cohort. Conclusion: Expression levels of FGFR1 protein may be an independent prognostic factor in terms of RFS for ER-positive/HER2-negative breast cancer patients receiving standard care. Citation Format: Tomiguchi M, Yamamoto Y, Yamamoto-Ibusuki M, Yamaguchi R, Fujiki Y, Fujiwara S, Sueta A, Takeshita T, Inao T, Iwase H. FGFR1 protein expression is associated with prognosis in primary breast cancer: A comprehensive analysis of gene copy number, mRNA and protein expression. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-09-01.
Detection and Sizing of Acute Myocardial Infarcts with<sup>99m</sup>Tc (Sn) Tetracycline
Authors: B. Leonard Holman, Michael Lesch, Franklin G. Zweiman, John Temte, Bernard Lown, Richard Gorlin
Journal: New England Journal of Medicine (1974)

Myocardial scintigraphy was performed in 28 patients with the technetium chelate, 99mTc (Sn) tetracycline. Acutely infarcted myocardium was visualized as an area of increased radioactivity. All 14 patients with definite clinical evidence of acute myocardial infarction and two of five patients in whom the evidence of infarction was equivocal had abnormal scintigrams. Scintigraphy gave normal results in nine patients in whom an acute lesion failed to evolve. Peak activity occurred one to three days after the clinical onset of chest pain. Old infarcts did not concentrate 99mTc (Sn) tetracycline. (N Engl J Med 291:159–163, 1974)
Expression profile of CTC and corresponding tumors in primary breast cancer patients
Authors: F. N. Tanja, O. Hoffmann, B. Aktas, E. Solomayer, D. Wallwiener, S. Becker, R. Kimmig, S. Kasimir-Baur
Journal: Journal of Clinical Oncology (2009)

538 Background: The target of adjuvant therapy in breast cancer is minimal residual disease (MRD). However, treatment decisions are based on expression of predictive markers (ER; PR, HER-2) of the primary tumor. Based on current studies, presence of MRD may be reflected by the detection of circulating tumor cells (CTC). Therefore, the aim of the study was to characterize CTC by multiplex-PCR for the expression of HER-2, ER, and PR and compare the expression profiles of CTCs with those of the corresponding primary tumors. Methods: CTC from blood of 431 patients with primary breast cancer were analyzed for EpCAM, MUC1, and HER-2 transcripts with the AdnaTest BreastCancer (AdnaGen AG, Germany). A blood samples was CTC positive when at least one of the markers was detected. Expression of the ER and PR receptor was assessed in an additional RT-PCR. The ER, PR and HER2 receptor status of the primary tumors was determined by immunohistochemistry. The DAKO-Score for the expression of HER-2 was determined with the HercepTest. Results: The overall detection rate for CTC was 13% (58/431 patients) with the expression rates of 38% for HER-2 (22/58 patients), 25% for ER (12/48) and 4% for PR (2/48), respectively. ER positivity of the primary tumor was demonstrated in 45/58 (78%) of these patients, PR positivity in 41/58 (71%) patients and HER-2 in 9/58 (16%) patients, respectively. The concordance rate between ER, PR, and HER-2 status of CTCs and the primary tumor was 29%, 25%, and 53%, respectively Interestingly, the spread of CTC was mostly found in triple negative tumors (p = 0.01) and CTC in general were mostly found to be triple-negative regardless of the ER, PR, and HER-2 status of the primary tumor. Conclusions: Since the expression profile between CTC and the primary tumor differs, the consequence for the selection of adjuvant treatment targeting minimal residual disease has to be further evaluated in clinical trials. No significant financial relationships to disclose.
Intratibial Moloney Sarcoma Virus-Induced Osteosarcoma in the Rat: Tumor Incidence and Pathologic Evaluation2
Authors: Harry M. Olson, Charles C. Capen
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Intratibial Moloney Sarcoma Virus-Induced Osteosarcoma in the Rat: Tumor Incidence and Pathologic Evaluation Get access Harry M. Olson, Harry M. Olson Search for other works by this author on: Oxford Academic PubMed Google Scholar Charles C. Capen Charles C. Capen Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 2, February 1977, Pages 433–437, https://doi.org/10.1093/jnci/58.2.433 Published: 01 February 1977 Article history Received: 05 April 1976 Accepted: 24 June 1976 Published: 01 February 1977
IMPS-03INTRATUMORAL REGULATED EXPRESSION OF IL-12 AS A GENE THERAPY APPROACH TO TREATMENT OF GLIOMA
Authors: John A. Barrett, Hongliang Cai, John Miao, Margaret Murray, Emily Gable, Deborhah Blake, Suma Krishnan, E. Antonio Chiocca, Seema Nagpal, Jeffery Raizer, John Yu, Francois Lebel
Journal: Neuro-Oncology (2015)

Immunotherapy is an attractive approach for glioma therapy. We have developed a replication-incompetent adenovirus engineered to express IL-12 (Ad-RTS-IL-12), via our RheoSwitch Therapeutic System® (RTS®) gene switch, injected directly into a tumor. IL-12 expression is off devoid of the activator ligand, veledimex, while IL-12 production is turned  (in a dose-dependent manner) by oral administration of veledimex. Mechanistic studies in numerous syngeneic mouse tumor models with Ad-RTS-mIL-12 + veledimex have demonstrated a dose-related increase in tumor IL-12 mRNA and IL-12 protein expression. Discontinuation of veledimex resulted in a return to baseline IL-12 mRNA and protein expression. These changes correlated with a local and systemic immune and anti-tumor response. Veledimex crossed the blood-brain-barrier in both naive and orthotopic GL-261 mice with increased brain tissue level of ∼6 fold observed in tumor bearing vs. normal mice (1950 ± 573 and 324 ± 51ng/g). Based on these findings the effects of Ad-RTS-mIL-12(5e9vp) + veledimex were studied in the following cohorts; dexamethasone, bevacizumab, temozolamide and CD279 (PD-1 inhibitor). Ad-RTS-mIL-12 + veledimex demonstrated a dose-related increase in survival without significant adverse events. At Day 92 (study termination), 50% of the animals that received veledimex at 100mg/m2/day for 14 consecutive days were alive and tumor free with peak tumor IL-12 at Day 3 of ∼240pg/mg. In contrast, the mean survival for the other groups were: vehicle 18d, dexamethasone 24d, bevacizumab 25d, temozolamide 40d and CD279 38d demonstrating that this novel regulated immunotherapeutic approach may be an effective form of therapy for glioma. A Phase 1 study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or progressive malignant glioma are stratified into two groups: resection plus localized injection or stereotactic injection (3D-located) of Ad-RTS-hIL-12 (single intratumoral injection) + veledimex 14 days (oral) has initiated. The primary endpoint is the safety and tolerability of Ad-RTS-hIL-12 + veledimex with secondary endpoints of MTD, immune response, objective response rate, disease progression, progression-free and overall survival.
Coffee and Myocardial Infarction
Authors: Hershel Jick, Olli S. Miettinen, Raymond K. Neff, Samuel Shapiro, Olli P. Heinonen, Dennis Slone
Journal: New England Journal of Medicine (1973)

A positive association between coffee consumption and acute myocardial infarction was confirmed by analyses of data from a multipurpose survey of 12,759 hospitalized patients, including 440 with a diagnosis of acute myocardial infarction. As compared with those who drink no coffee, the risks of infarction among those drinking one to five and six or more cups of coffee per day are estimated to be increased by 60 and 120 per cent, respectively. This association could not be attributed to confounding by age, sex, past coronary heart disease, hypertension, congestive heart failure, obesity, diabetes, smoking or occupation, nor could it be explained by the use of sugar with coffee. There was no positive association between tea drinking and acute myocardial infarction. (N Engl J Med 289:63–67, 1973)
Absence of Benefit of Eradicating<i>Helicobacter pylori</i>in Patients with Nonulcer Dyspepsia
Authors: Nicholas J. Talley, Nimish Vakil, E. David Ballard, M. Brian Fennerty
Journal: New England Journal of Medicine (1999)

The relation between Helicobacter pylori infection and nonulcer dyspepsia is uncertain. We tested the hypothesis that curing the infection will relieve symptoms of dyspepsia.
Heparin-Induced Immune Thrombocytopenia
Authors: Robert B. Babcock, C. Wesley Dumper, William B. Scharfman
Journal: New England Journal of Medicine (1976)

We studied five patients in whom severe thrombocytopenia developed during intermittent intravenous heparin treatment of arterial and venous thrombosis. Platelet aggregation was demonstrated when heparin (0.5 U per milliliter) was incubated with the patients' citrated platelet-rich plasma or with normal platelet-rich plasma in the presence of the patients' serum. Antiplatelet antibody was not detected in the patient globulin fractions prepared from serum collected within one week after heparin withdrawal by use of the platelet factor 3 availability technic. When the studies were repeated with modifications to detect heparin-dependent antiplatelet antibodies, positive results were obtained in four of five patients. The data suggest that a causal relation, mediated by an immune mechanism, existed between heparin therapy and thrombocytopenia, and that this syndrome may occur more often than has previously been suspected. (N Engl J Med 295:237–241, 1976)
Compliance and Nutritional Status During Feasibility Study for an Intervention Trial in China&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;
Authors: Abby G. Ershow
 3, Su-Fang Zheng, Guangyi Li, Junyao Li, Chung S. Yang, William J. Blot
Journal: JNCI Journal of the National Cancer Institute (1984)

As part of a pilot study to assess the feasibility of a long-term intervention trial to be done in Linxian, People's Republic of China, nutritional status and compliance were assessed in villagers taking daily multivitamin pills containing the U.S. Recommended Dietary Allowances (RDA). Before the start of the trial and again during its 4th month, nutritional status was assessed by laboratory tests and a dietary interview. Compliance was assessed in all subjects by pill counts and in a subset by urinary riboflavin loading-dose tests. At the outset of the trial, the study population had widespread biochemical and dietary deficiencies of ascorbic acid and riboflavin. As expected, subjects taking a daily pill had significantly improved status for these vitamins during the study. Compliance as measured by pill counts was excellent, with over 90% of the subjects taking at least 80% of their daily pills. Mean urinary excretion of a riboflavin loading dose entered and remained in the normal range after 3 weeks of supplementation, indicating that compliance did not fall off over time. Compliance was similar in normal subjects and in those with a prior diagnosis of esophageal dysplasia. Compliance also was nearly as good in subjects receiving monthly home visits as in those receiving weekly home visits from the barefoot doctor (village paramedical worker). The results of this pilot study indicated that a long-term intervention trial was feasible in Linxian and that the RDA dose level of vitamins was effective in ameliorating certain nutritional deficiencies prevalent in the study population.
Prevention Strategies for Contrast-Induced Nephropathy
Authors: Eric B. Bass
Journal: Annals of Internal Medicine (2016)

Letters5 April 2016Prevention Strategies for Contrast-Induced NephropathyEric B. Bass, MD, MPHEric B. Bass, MD, MPHFrom Evidence-based Practice Center, Johns Hopkins University, Baltimore, Maryland.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0097 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:My coauthors and I thank Drs. Weisbord and Palevsky for calling our attention to questions regarding our recent article. We summarize our responses below.We agree that the text should be clearer about how studies of N-acetylcysteine generally compared N-acetylcysteine plus IV saline to IV saline with or without placebo. This is also true for studies of statins and ascorbic acid, with use of IV saline in the intervention and comparator groups. To make this clearer, we have replaced Appendix Tables 2 with a data Supplement to present a more detailed version of the information about use of ... Author, Article, and Disclosure InformationAffiliations: From Evidence-based Practice Center, Johns Hopkins University, Baltimore, Maryland.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOf InterestForms.do?msNum=L16-0097. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffectiveness of Prevention Strategies for Contrast-Induced Nephropathy Rathan M. Subramaniam , Catalina Suarez-Cuervo , Renee F. Wilson , Sharon Turban , Allen Zhang , Cheryl Sherrod , Jonathan Aboagye , John Eng , Michael J. Choi , Susan Hutfless , and Eric B. Bass Prevention Strategies for Contrast-Induced Nephropathy Steven D. Weisbord and Paul M. Palevsky Metrics 5 April 2016Volume 164, Issue 7Page: 511-512KeywordsBicarbonatesCervical intraepithelial neoplasiaChronic kidney diseaseDiabetes mellitusHeart diseasesRisk managementRoutes of administrationSaline solutionsSodiumStatins ePublished: 5 April 2016 Issue Published: 5 April 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Long-term results of primary re-excision after unplanned resection of a soft tissue sarcoma of the extremities and trunk.
Authors: M. Peiper, A. Rehders, E. Boelke, W. Budach, C. Poremba, W. Knoefel
Journal: Journal of Clinical Oncology (2010)

10088 Background: Soft tissue sarcomas are often treated by inadequate resection lacking oncological strategies, resulting in a local recurrence rate of up to 90%. The concept of re-excision in these patients is under debate. Our goal was to evaluate the results of this treatment with particular respect to residual tumor. Methods: During 14 years 143 patients were referred to our institution after unplanned excision of a soft tissue sarcoma of the extremities and trunk. Reexcision was performed in 139 patients after complete clinical staging. Endpoints were local recurrence-free survival, distant metastasis-free survival, and tumor-related mortality. Univariate and multivariate analyses were performed (log-rank test and Cox's proportional-hazard models). Results: In 78 males and 61 females primary re-excision resulted in a R0 status in 96% (n=133) and R1 in 4% (n=6).Resections included wide resection (n=108) and compartmental resection (n=31); no amputation was performed.Most common histological types were liposarcoma (n=39), MFH (n=36), and leiomyosarcoma (n=15). 59 tumors were graded G3, 41 G2, and 39 G1, while 90 tumors were pT2 and 49 tumors pT1.Three patients (2%) presented with regional lymph nodes metastases, none with distant metastases. Residual tumor in the specimen was detected in 43 patients (31%). Over a median observation period of 109 months, local recurrence was detected in 18 patients (12%) and distant metastasis in 46 patients (33%).The median relapse-free survival time was 98 months with 5-year and 10-year survival rates of 64% and 59%. Metastases-free survival and overall survival were significantly reduced if residual tumor was detected (p=0.0024 and p=0.0007).Clinicopathological factors negatively associated with relapse-free survival included pT2x (p=0.009), N1 (p=0.0051), Txb (tumor depth, p=0.042), G3 (p<0.001), and residual detected tumor in the specimen (p=0.002), (multivariate analysis). Conclusions: Despite an initial resection neglecting oncological principles, primary re-excision enables local tumor control similar to patients with initial resection. There is an increased risk of distant metastases, if residual tumor is detected. No significant financial relationships to disclose.